id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2008-D-0525-0012,FDA,FDA-2008-D-0525,Guidance for Industry on New Contrast Imaging Indication Considerations for Devices and Approved Drug and Biological Products; Availability,Notice,NAD-Notice of Availability of Data,2010-01-06T05:00:00Z,2010,1,2010-01-06T05:00:00Z,,2010-01-06T12:59:25Z,E9-31307,0,0,0900006480a77902
FDA-2008-D-0525-0013,FDA,FDA-2008-D-0525,New Contrast Imaging Indication Considerations for Devices and Approved Drug and Biological Products:  Guidance for Industry,Other,Guidance,2009-12-31T05:00:00Z,2009,12,2009-12-31T05:00:00Z,,2024-11-07T22:12:12Z,,1,0,0900006480a77652
FDA-2008-D-0525-0001,FDA,FDA-2008-D-0525,Draft Guidance for Industry on New Contrast Imaging Indication Considerations for Devices and Approved Drug and Biological Products; Availability,Notice,NAD-Notice of Availability of Data,2008-10-07T04:00:00Z,2008,10,2008-10-07T04:00:00Z,2009-01-06T04:59:59Z,2024-11-07T21:57:35Z,E8-23712,1,0,090000648073b491
FDA-2008-D-0525-0002,FDA,FDA-2008-D-0525,Guidance for Industry: New Contrast Imaging Indication Considerations for Devices and Approved Drug and Biological Products - Draft Guidance,Other,GDL-Guidance (Supporting and Related Materials),2008-10-07T04:00:00Z,2008,10,,,2024-11-07T21:55:50Z,,1,0,090000648073b807